Erlangen – KI-VesD (German title: Diagnostik mit Biomarkern aus extrazellulären Vesikeln (EV) mit Methoden der künstlichen Intelligenz) started its initial funding period in September 2020. On the occassion of its extension, the project members organized a progress workshop. Seven speakers from all contributing institutions presented recent advances in the scientific and clinical branches and discussed them in the public plenum.
The results were seen as promising, and additional clinical trials for prostate carcinoma, melanoma, and lymphoma are planned, the latter in a multi-center setting. The team is looking to acquire additional funding for these studies. Similarly, the engineering part of the project is progressing nicely. A first prototype for the automated purifciation of plasma vesicles has been built and introduced.
